David Moatazedi Sells 64,211 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS – Get Rating) insider David Moatazedi sold 64,211 shares of Evolus stock in a transaction that occurred on Tuesday, March 14th. The stock was sold at an average price of $8.47, for a total value of $543,867.17. Following the sale, the insider now owns 615,677 shares in the company, valued at $5,214,784.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Evolus Stock Down 1.4 %

EOLS stock opened at $8.37 on Friday. The firm has a market cap of $472.15 million, a price-to-earnings ratio of -6.34 and a beta of 1.93. Evolus, Inc. has a 1-year low of $6.51 and a 1-year high of $14.34. The firm has a fifty day moving average price of $9.26 and a two-hundred day moving average price of $8.53. The company has a debt-to-equity ratio of 3.89, a current ratio of 2.17 and a quick ratio of 1.76.

Wall Street Analyst Weigh In

EOLS has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $18.00 price target on shares of Evolus in a research note on Thursday, March 9th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Evolus in a research report on Thursday, March 9th. SVB Leerink upped their target price on shares of Evolus from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday, January 19th. Finally, Mizuho lifted their price target on Evolus from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, January 19th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd raised its stake in Evolus by 979.7% during the first quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock worth $26,000 after acquiring an additional 2,126 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in shares of Evolus during the 1st quarter worth approximately $26,000. Point72 Middle East FZE bought a new stake in shares of Evolus in the 4th quarter worth approximately $39,000. Tower Research Capital LLC TRC boosted its position in Evolus by 453.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $51,000 after purchasing an additional 5,221 shares during the period. Finally, Ensign Peak Advisors Inc acquired a new position in Evolus during the 3rd quarter valued at approximately $54,000. 45.41% of the stock is owned by institutional investors and hedge funds.

Evolus Company Profile

(Get Rating)

Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.